PCOS Has a New Name: What Polyendocrine Metabolic Ovarian Syndrome Means
Polycystic ovary syndrome, widely known as PCOS, has officially been given a new name: Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The change was announced in May 2026 following a major international consensus process involving patients, clinicians, researchers and professional organisations. The new terminology was published in The Lancet and reflects a broader understanding of a condition that extends beyond the ovaries.
For people already diagnosed with PCOS, this does not mean that they now have a different condition. The change is primarily about using terminology that describes the condition more accurately.
Why Has PCOS Been Renamed PMOS?
The term “polycystic ovary syndrome” has been questioned for many years because it can give an inaccurate impression of what the condition involves.
In particular, the word “polycystic” suggests that abnormal ovarian cysts are central to the condition. However, the structures often seen on an ultrasound are ovarian follicles rather than pathological cysts, and ovarian appearance alone does not define the syndrome.
PCOS can involve a much wider range of features, including:
- irregular menstrual cycles
- raised androgen levels
- excess hair growth and acne
- difficulties with ovulation and fertility
- metabolic factors such as insulin resistance
These features highlight that the condition can affect reproductive, hormonal and metabolic health. The previous name therefore placed considerable emphasis on the ovaries despite the broader nature of the condition.
Polyendocrine Metabolic Ovarian Syndrome is intended to describe this wider clinical picture more accurately.
Polyendocrine Metabolic Ovarian Syndrome: What Does It Mean?
Polyendocrine refers to the involvement of multiple hormonal and endocrine processes. PMOS is not limited to ovarian function. Changes in hormone regulation can affect menstrual function, androgen levels, ovulation and other aspects of health.
Metabolic recognises the important relationship between the condition and metabolic health. Insulin resistance is common in people with PCOS or PMOS, although it does not occur in every patient. Metabolic assessment may therefore form an important part of care alongside reproductive and hormonal evaluation.
Ovarian remains in the name because ovarian function is still an important part of the syndrome. Irregular ovulation, menstrual changes and fertility difficulties can all occur, but they sit within a broader endocrine and metabolic condition.
This change in terminology may help move the clinical focus away from the assumption that PCOS is solely a gynaecological or fertility issue.
How Was the New PMOS Name Decided?
The international process developed over approximately 14 years and involved 56 patient and professional organisations. More than 22,000 survey responses contributed to the wider consultation and research process, alongside international workshops involving people with the condition and healthcare professionals from multiple disciplines.
The aim was to identify terminology that was scientifically accurate, understandable, culturally appropriate and less likely to cause confusion or stigma.
The process ultimately resulted in the name Polyendocrine Metabolic Ovarian Syndrome, formally presented in 2026.
A three-year transition period is now underway. The new terminology is expected to be fully incorporated into the next International Evidence-based Guideline for the condition, planned for 2028.
What Does the New Name Mean for Patients?
Someone previously diagnosed with PCOS does not need a new diagnosis simply because the term PMOS is being introduced. Both terms are likely to appear in medical records, research and clinical discussions during the transition period.
The more significant change is how the condition is understood. The new name gives greater prominence to metabolic and endocrine health alongside menstrual symptoms, ovarian function and fertility, supporting a more comprehensive approach to assessment and long-term care.
Patients experiencing irregular periods, symptoms of androgen excess, difficulties with weight or metabolic health, or concerns about an existing PCOS or PMOS diagnosis should discuss appropriate assessment with a healthcare professional rather than relying on symptoms alone.
PCOS/PMOS Care at London Lauriston Clinic
While the terminology is changing, individual assessment remains important because PMOS can present differently from one person to another.
London Lauriston Clinic is a private healthcare clinic in central London offering specialist diabetes and endocrinology consultations, including assessment and management of PCOS and related hormonal and metabolic concerns.
Patients who would like to discuss symptoms, an existing PCOS/PMOS diagnosis, or whether further endocrine assessment may be appropriate can contact London Lauriston Clinic at info@llclinics.co.uk or call 020 4511 0444 to arrange a consultation.
